Edition:
India

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

0.50USD
10:43pm IST
Change (% chg)

$-0.04 (-6.56%)
Prev Close
$0.53
Open
$0.53
Day's High
$0.53
Day's Low
$0.48
Volume
108,106
Avg. Vol
152,327
52-wk High
$3.00
52-wk Low
$0.48

Latest Key Developments (Source: Significant Developments)

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets
Thursday, 27 Jun 2019 

June 27 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY LAUNCHES CAMPAIGN EXPLORING NON-DILUTIVE STRATEGIC OPTIONS TO SUPPORT DEVELOPMENT OF ITS DDR ASSETS.SIERRA ONCOLOGY INC - EXPLORING NON-DILUTIVE OPTIONS TO SUPPORT FUTURE CONTINUED DEVELOPMENT OF SRA737 AND SRA141.SIERRA ONCOLOGY INC - CORPORATE PRIORITIZATION OF PORTFOLIO TO FOCUS RESOURCES ON ADVANCEMENT OF MOMELOTINIB.SIERRA ONCOLOGY INC - SIERRA PLANS TO LAUNCH MOMENTUM PHASE 3 CLINICAL TRIAL IN Q4 2019.  Full Article

Sierra Announces Momelotinib Granted FDA Fast Track Designation
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Sierra Oncology Inc ::SIERRA ANNOUNCES MOMELOTINIB GRANTED FDA FAST TRACK DESIGNATION.SIERRA ONCOLOGY INC - PLANS TO LAUNCH MOMENTUM PHASE 3 CLINICAL TRIAL IN Q4 2019.  Full Article

Sierra Announces FDA Regulatory Clarity For Momelotinib & Design Of The Momentum Phase 3 Clinical Trial
Wednesday, 5 Jun 2019 

June 4 (Reuters) - Sierra Oncology Inc ::SIERRA ANNOUNCES FDA REGULATORY CLARITY FOR MOMELOTINIB & DESIGN OF THE MOMENTUM PHASE 3 CLINICAL TRIAL.SIERRA ANNOUNCES FDA REGULATORY CLARITY FOR MOMELOTINIB & DESIGN OF THE MOMENTUM PHASE 3 CLINICAL TRIAL.SIERRA ONCOLOGY INC - MOMENTUM PHASE 3 CLINICAL TRIAL PLANNED FOR LAUNCH IN Q4 2019; TOPLINE EFFICACY DATA ANTICIPATED IN Q4 2021.SIERRA ONCOLOGY INC - STUDY POWERED 99% ON PRIMARY ENDPOINT OF SYMPTOMATIC BENEFIT; >90% POWERED ON SECONDARY ENDPOINTS OF ANEMIA BENEFIT AND SPLEEN REDUCTION.  Full Article

Sierra Oncology Reports Q1 Results
Wednesday, 8 May 2019 

May 8 (Reuters) - Sierra Oncology Inc ::QTRLY LOSS PER SHARE $0.17.CASH AND CASH EQUIVALENTS TOTALED $90.9 MILLION AS OF MARCH 31, 2019, COMPARED TO $106.0 MILLION AS OF DECEMBER 31, 2018.  Full Article

Sareum Holdings Says Sierra Oncology Reports Preclinical Data For SRA737 In Ovarian Cancer
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Sareum Holdings PLC ::PRECLINICAL DATA FOR SRA737 IN OVARIAN CANCER.SIERRA ONCOLOGY REPORTS SUPPORTIVE PRECLINICAL DATA FOR SRA737 IN OVARIAN CANCER MODELS.  Full Article

Sierra Oncology Reports Third Quarter Loss Per Share $0.21
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY REPORTS THIRD QUARTER RESULTS.SIERRA ONCOLOGY INC - CASH AND CASH EQUIVALENTS TOTALED $116.1 MILLION AS OF SEPTEMBER 30, 2018, COMPARED TO $100.3 MILLION AS OF DECEMBER 31, 2017.SIERRA ONCOLOGY INC - QTRLY LOSS PER SHARE $0.21.  Full Article

Sierra Oncology Obtains Debt Facility From Silicon Valley Bank To Acquire And Advance Momelotinib
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY OBTAINS DEBT FACILITY FROM SILICON VALLEY BANK TO ACQUIRE AND ADVANCE MOMELOTINIB.SIERRA ONCOLOGY - DEBT FACILITY INCLUDES UP TO $15 MILLION AVAILABLE IN THREE $5 MILLION TRANCHES.SIERRA ONCOLOGY - AN ADDITIONAL $25 MILLION IS POTENTIALLY AVAILABLE IN AN UNCOMMITTED INCREMENTAL FACILITY SUBJECT TO LENDER APPROVAL.  Full Article

Sierra Oncology Acquires Momelotinib From Gilead Sciences
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ACQUIRES MOMELOTINIB, AN INVESTIGATIONAL JANUS KINASE (JAK) 1/2 AND ACTIVIN RECEPTOR TYPE 1 (ACVR1) INHIBITOR FOR MYELOFIBROSIS, FROM GILEAD SCIENCES.SIERRA ONCOLOGY INC - WILL PAY GILEAD A $3 MILLION UPFRONT FEE FOR MOMELOTINIB AND POTENTIAL AGGREGATE MILESTONE PAYMENTS OF UP TO $195 MILLION.SIERRA ONCOLOGY INC - SIERRA WILL ASSUME ALL CURRENTLY ONGOING CLINICAL STUDIES WITH MOMELOTINIB FOLLOWING A TRANSITION PERIOD..SIERRA - TO ALSO PAY GILEAD ROYALTIES ON ANY SALES OF MOMELOTINIB, WHICH WILL BE TIERED BASED ON COMMERCIAL SUCCESS & RANGE FROM MID-TEENS TO HIGH-TWENTIES.  Full Article

Sierra Oncology Announces Pricing Of Public Offering Of Common Stock
Friday, 2 Mar 2018 

March 2 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 19.0 MILLION COMMON SHARES PRICED AT $2.25PER SHARE.  Full Article

Sierra Oncology Announces Proposed Public Offering Of Common Stock
Friday, 2 Mar 2018 

March 1 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SIERRA ONCOLOGY - INTENDS TO USE NET PROCEEDS FROM PUBLIC OFFERING TO FUND DEVELOPMENT OF ITS PRODUCT CANDIDATES, SRA737 AND SRA141.  Full Article